New Vaccine Technologies to Combat Outbreak Situations

Rauch, Susanne; Jasny, Edith; Schmidt, Kim E.; Petsch, Benjamin

doi:10.3389/fimmu.2018.01963

Cited by 579SARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesImmune responses and vaccinations

New Vaccine Technologies to Combat Outbreak Situations

Open access

Rauch, Susanne, Jasny, Edith, Schmidt, Kim E., Petsch, Benjamin·2018·Frontiers in Immunology

DOI 10.3389/fimmu.2018.01963PMC PMC6156540

Open this paper in CoChat — free account Open PDF

Abstract

Ever since the development of the first vaccine more than 200 years ago, vaccinations have greatly decreased the burden of infectious diseases worldwide, famously leading to the eradication of small pox and allowing the restriction of diseases such as polio, tetanus, diphtheria, and measles. A multitude of research efforts focuses on the improvement of established and the discovery of new vaccines such as the HPV (human papilloma virus) vaccine in 2006. However, radical changes in the density, age distribution and traveling habits of the population worldwide as well as the changing climate favor the emergence of old and new pathogens that bear the risk of becoming pandemic threats. In recent years, the rapid spread of severe infections such as HIV, SARS, Ebola, and Zika have highlighted the dire need for global preparedness for pandemics, which necessitates the extremely rapid development and comprehensive distribution of vaccines against potentially previously unknown pathogens. What is more, the emergence of antibiotic resistant bacteria calls for new approaches to prevent infections. Given these changes, established methods for the identification of new vaccine candidates are no longer sufficient to ensure global protection. Hence, new vaccine technologies able to achieve rapid development as well as large scale production are of pivotal importance. This review will discuss viral vector and nucleic acid-based vaccines (DNA and mRNA vaccines) as new approaches that might be able to tackle these challenges to global health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.01963

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The spike protein is a class I fusion protein that binds ACE2 on host cells and triggers virus-cell membrane fusion.
“The S protein is a class I fusion protein that facilitates binding of the virus to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface, which triggers fusion between the virus and cell membrane110,148,149.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [149]
Traditionally, vaccine development takes more than 10 years.
“Traditionally, vaccine development takes more than 10 years122”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [122]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574 · see citing works
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1× · see citing works
“DNA vaccines in potential pandemic settings Since the first experiments in the 1990 (91), DNA vaccines have been employed for vaccine development up to clinical trials against a large variety of human pathogens such as HIV, influenza virus, malaria, hepatitis B virus, respiratory syncytial and herpes simplex virus.”
Background
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903810 · Cited by 3,047 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
Updating the accounts: global mortality of the 1918–1920 "Spanish" influenza pandemic.
Johnson, N. P. A. S., & Mueller, J. (2002) · Bulletin of the History of Medicine · doi:10.1353/bhm.2002.0022 · Cited by 1,980 · see citing works
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · see citing works
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · see citing works
Codon bias and heterologous protein expression
Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330 · see citing works
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · see citing works
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
Restrepo, A. M. H., Camacho, A., Longini, I. M., Watson, C., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I. D., Doumbia, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,112 · see citing works
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014 · see citing works
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · see citing works
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 892 · see citing works
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works
The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.
Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868 · see citing works
The enzymes and control of eukaryotic mRNA turnover
Parker, R., & Song, H. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb724 · Cited by 813 · see citing works
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
Restrepo, A. M. H., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M. M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 794 · see citing works
Koch's postulates fulfilled for SARS virus
Fouchier, R. A. M., Kuiken, T., Schutten, M., van Amerongen, G., van Doornum, G. J. J., van den Hoogen, B. G., Peiris, M. J. S., Lim, W. W. L., Stöhr, K., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/423240a · Cited by 790 · see citing works
N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · see citing works
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · see citing works
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., Klenk, H. D., Sullivan, N. J., Volchkov, V. E., Fritz, E. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1258 · Cited by 687 · see citing works
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 2× · see citing works
“Upon injection in mice, LNP-formulated selfamplifying mRNA encoding firefly luciferase induced protein expression lasting almost two months upon IM delivery (130), while luciferase expression from protamine-formulated, nonreplicating mRNA administered ID was usually only detected for several days (133).”
Background
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 655 · see citing works
Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622 · see citing works
Recombinant vesicular stomatitis viruses from DNA.
Lawson, N. D., Stillman, E. A., Whitt, M. A., & Rose, J. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4477 · Cited by 617 · see citing works
Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization
Porgador, A., Irvine, K. R., Iwasaki, A., Barber, B. H., Restifo, N. P., & Germain, R. N. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1075 · Cited by 560 · see citing works
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555 · see citing works
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530 · see citing works
Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · cited 1× · see citing works
“As shown by Thess and colleagues, sequenceoptimized, unmodifiedmRNA led to higher protein expression in vitro in HeLa cells and in vivo in mice than the respective mRNA containing modified nucleosides (123).”
Background
Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501 · see citing works
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476 · see citing works
Gene vaccination with naked plasmid DNA: mechanism of CTL priming.
Corr, M., Lee, D. J., Carson, D. A., & Tighe, H. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1555 · Cited by 476 · see citing works
Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover
Yamashita, A., Chang, T.-C., Yamashita, Y., Zhu, W., Zhong, Z., Chen, C. A., & Shyu, A. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1016 · Cited by 472 · see citing works
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Xu, L., Yang, Z., Roederer, M., Koup, R. A., Jahrling, P. B., & Nabel, G. J. (2003) · Nature · doi:10.1038/nature01876 · Cited by 464 · see citing works
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo
Chen, Z.-Y., He, C.-Y., Ehrhardt, A., & Kay, M. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00168-0 · Cited by 463 · see citing works
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 461 · see citing works
Self-citation
DNA Vaccines: Progress and Challenges
Donnelly, J., Wahrén, B., & Liu, M. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.633 · Cited by 449 · see citing works
The complexity and cost of vaccine manufacturing – An overview
Plotkin, S. A., Robinson, J. M., Cunningham, G., Iqbal, R., & Larsen, S. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.06.003 · Cited by 437 · see citing works
Electroporation delivery of DNA vaccines: prospects for success
Sardesai, N. Y., & Weiner, D. B. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.008 · Cited by 416 · see citing works
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Agnandji, S. T., Huttner, A. C., Zinser, M. E., Njuguna, P., Dahlke, C., Fernandes, J. F., Yerly, S., Dayer, J.-A., Krähling, V., Kasonta, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502924 · Cited by 415 · see citing works
Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414 · see citing works
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 400 · see citing works
Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses
Garbutt, M., Liebscher, R., Wahl‐Jensen, V., Jones, S. J. M., Möller, P., Wagner, R., Volchkov, V. E., Klenk, H., Feldmann, H., & Ströher, U. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5458-5465.2004 · Cited by 396 · see citing works
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395 · see citing works
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389 · see citing works
Viral vectors: from virology to transgene expression
Bouard, D., Alazard-Dany, N., & Cosset, F. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.349 · Cited by 359 · see citing works
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 1× · see citing works
“An increasing number of preclinical studies have shown promising results for both self-amplifying and non-replicating mRNA vaccines to confer protection against various pathogens, including those with pandemic potential (162, (173) (174) (175) (176) .”
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
Stanley, D. A., Honko, A. N., Asiedu, C. K., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L. E., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350 · see citing works
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348 · see citing works
Untitled work
(2001) · PubMed Central · Cited by 342 · see citing works
Vaccines, new opportunities for a new society
Rappuoli, R., Pizza, M., Giudice, G. D., & Gregorio, E. D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402981111 · Cited by 337 · see citing works
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335 · see citing works
Molecular mechanisms for enhanced DNA vaccine immunogenicity
Li, L., & Petrovsky, N. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1124762 · Cited by 334 · see citing works
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine
Tebas, P., Roberts, C. C., Muthumani, K., Reuschel, E. L., Kudchodkar, S. B., Zaidi, F. I., White, S., Khan, A. S., Racine, T., Choi, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708120 · Cited by 328 · see citing works
Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation
Wang, Z., Troilo, P. J., Wang, X., Griffiths, T. G., Pacchione, S. J., Barnum, A. B., Harper, L. B., Pauley, C. J., Niu, Z., Denisova, L., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302213 · Cited by 323 · see citing works
Filoviruses in Bats: Current Knowledge and Future Directions
Olival, K. J., & Hayman, D. T. S. (2014) · Viruses · doi:10.3390/v6041759 · Cited by 312 · see citing works
Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309 · see citing works
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Gaudinski, M. R., Houser, K. V., Morabito, K. M., Hu, Z., Yamshchikov, G. V., Rothwell, R. S., Berkowitz, N. M., Mendoza, F. H., Saunders, J. G., Novik, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)33105-7 · Cited by 302 · see citing works
Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes
Fu, T., Ulmer, J. B., Caulfield, M. J., Deck, R. R., Friedman, A., Wang, S., Liu, X., Donnelly, J., Liu, M. A., & Wigzell, H. (1997) · Molecular Medicine · doi:10.1007/bf03401683 · Cited by 296 · see citing works
Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282 · see citing works
Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A. (2013) · Science · doi:10.1126/science.1232910 · Cited by 282 · see citing works
Designing Tomorrow's Vaccines
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271 · see citing works
Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease
Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., Himansu, S., Caine, E. A., Nunes, B. T. D., Medeiros, D. B. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.040 · Cited by 267 · see citing works
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · cited 7× · see citing works
“Furthermore, 10 μg of a comparable HA encoding vaccine delivered IM as LNP formulation elicited functional antibody responses in NHPs, that remained stable over a duration of one year, with HI titer remaining above 1:40 as the surrogate measure of protection in humans (141).”
BackgroundInfluentialSelf-citation
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
Acosta, P. L., Caballero, M. T., & Polack, F. P. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00609-15 · Cited by 254 · see citing works
Risk in vaccine research and development quantified
Pronker, E. S., Weenen, T. C., Commandeur, H., Claassen, E. H. J. H. M., & Osterhaus, A. D. M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057755 · Cited by 253 · see citing works
Vesicular Stomatitis
Letchworth, G. J., Rodrı́guez, L. L., & CBARRERA, J. D. (1999) · The Veterinary Journal · doi:10.1053/tvjl.1998.0303 · Cited by 253 · see citing works
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia
Kennedy, S. B., Bolay, F. K., Kieh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614067 · Cited by 252 · see citing works
The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites
Iwasaki, A., Torres, C. A., Ohashi, P. S., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.11 · Cited by 249 · see citing works
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial
Ramsauer, K., Schwameis, M., Firbas, C., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70043-5 · Cited by 241 · see citing works
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
Martin, J. E., Sullivan, N. J., Enama, M. E., et al. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00162-06 · Cited by 235 · see citing works
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · see citing works
Clinical potential of electroporation for gene therapy and DNA vaccine delivery
Lambricht, L., Lopes, A., Kos, Š., et al. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1121990 · Cited by 231 · see citing works
Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice
Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., et al. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.54 · Cited by 226 · see citing works
<scp>RNA</scp> sensors of the innate immune system and their detection of pathogens
Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017) · IUBMB Life · doi:10.1002/iub.1625 · Cited by 225 · see citing works
A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223 · see citing works
Self-citation
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
Tapia, M. D., Sow, S. O., Lyke, K. E., Haidara, F. C., Diallo, F., Doumbia, M. M., Traoré, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00362-x · Cited by 219 · see citing works
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
O’Hara, G. A., Duncan, C. J. A., Ewer, K., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes‐Sandoval, A., Bird, P., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir850 · Cited by 214 · see citing works
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212 · cited 1× · see citing works
“This vaccine format has proved to be immunogenic and capable of inducting protection against lethal challenge infections with influenza or rabies virus in several animal models (124, 151).”
BackgroundSelf-citation
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
Ledgerwood, J. E., Costner, P. J. M., Desai, N., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.10.037 · Cited by 210 · see citing works
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 209 · see citing works
Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design
Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208 · see citing works
Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030177 · Cited by 205 · see citing works
In Vitro Transcription of Long RNA Containing Modified Nucleosides
Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204 · see citing works
Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA
Scheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M. P., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425656 · Cited by 198 · see citing works
Immunization for Ebola virus infection
Xu, L., Sanchez, A., Yang, Z., Zaki, S. R., Nabel, E. G., Nichol, S. T., & Nabel, G. J. (1998) · Nature Medicine · doi:10.1038/nm0198-037 · Cited by 196 · see citing works
Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
Edwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186 · see citing works
Self-citation
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Zhu, F., Hou, L., Li, J., Wu, S., Liu, P., Zhang, G., Hu, Y., Meng, F., Xu, J., Tang, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60553-0 · Cited by 184 · see citing works
Plasmid DNA Vaccines: Tissue Distribution and Effects of DNA Sequence, Adjuvants and Delivery Method on Integration into Host DNA
Manam, S., Ledwith, B. J., Barnum, A. B., Troilo, P. J., Pauley, C. J., Harper, L. B., Griffiths, T. G., Niu, Z., Denisova, L., Follmer, T. T., et al. (2000) · Intervirology · doi:10.1159/000053994 · Cited by 183 · see citing works
Self-Amplifying mRNA Vaccines
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 182 · see citing works
Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion
Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181 · see citing works
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180 · see citing works
Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease
Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178 · see citing works
DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal Challenge
Vanderzanden, L., Bray, M., FULLER, D. H., et al. (1998) · Virology · doi:10.1006/viro.1998.9176 · Cited by 172 · see citing works
An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector
Perri, S., Greer, C. E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R. E., Tang, Z., Bin, Q., Dubensky, T. W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10394-10403.2003 · Cited by 172 · see citing works
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production
Williams, J. (2013) · Vaccines · doi:10.3390/vaccines1030225 · Cited by 166 · see citing works
An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model
Chahal, J. S., Fang, T., Woodham, A. W., Khan, O. F., Ling, J. J., Anderson, D. G., & Ploegh, H. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-00193-w · Cited by 161 · see citing works
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates
Johnson, J. E., Nasar, F., Coleman, J. W., et al. (2006) · Virology · doi:10.1016/j.virol.2006.10.026 · Cited by 159 · see citing works
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154 · see citing works
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
Santis, O. D., Audran, R., Pothin, E., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00486-7 · Cited by 152 · see citing works
Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization.
Qiu, P., Ziegelhoffer, P. R., Sun, J., & Yang, N. S. (1996) · PubMed · Cited by 150 · see citing works
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
Carralot, J.-P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H.-G., & Pascolo, S. (2004) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-004-4255-0 · Cited by 149 · see citing works
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
Reperant, L. A., & Osterhaus, A. D. M. E. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.082 · Cited by 148 · see citing works
Novel viral vectors in infectious diseases
Humphreys, I. R., & Sebastian, S. (2017) · Immunology · doi:10.1111/imm.12829 · Cited by 148 · see citing works
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
Frey, S. E., Wald, A., Edupuganti, S., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.075 · Cited by 148 · see citing works
Paper: Epidemiological notes on some viruses isolated in Uganda (Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses)
Dick, G. W. A. (1953) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(53)90021-2 · Cited by 143 · see citing works
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
Muthumani, K., Griffin, B. D., Agarwal, S., et al. (2016) · npj Vaccines · doi:10.1038/npjvaccines.2016.21 · Cited by 137 · see citing works
Induction of robust B cell responses after influenza mRNA vaccination Is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells
Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132 · see citing works
Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
Sarwar, U. N., Costner, P. J. M., Enama, M. E., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu511 · Cited by 131 · see citing works
Nucleoside modified mRNA vaccines for infectious diseases
Pardi, N., & Weissman, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_6 · Cited by 129 · see citing works
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial
Kibuuka, H. N., Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A., Costner, P. J. M., Sitar, S., Glover, D., Hu, Z., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)62385-0 · Cited by 129 · see citing works
Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J. B., Gregorio, E. D., Geall, A. J., Brazzoli, M., & Bertholet, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161193 · Cited by 127 · see citing works
The tobacco etch viral 5′ leader and poly(A) tail are functionally synergistic regulators of translation
Gallie, D., Tanguay, R. L., & Leathers, V. L. (1995) · Gene · doi:10.1016/0378-1119(95)00521-7 · Cited by 125 · see citing works
Preclinical and Clinical Safety Studies on DNA Vaccines
Schalk, J. A. C., Mooi, F. R., Berbers, G. A. M., van Aerts, L., Ovelgönne, H., & Kimman, T. G. (2006) · Human Vaccines · doi:10.4161/hv.2.2.2620 · Cited by 125 · see citing works
Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes
Ross, J., & Sullivan, T. (1985) · Blood · doi:10.1182/blood.v66.5.1149.1149 · Cited by 121 · see citing works
Mimicking live flavivirus immunization with a noninfectious RNA vaccine
Kofler, R. M., Aberle, J. H., Aberle, S. W., Allison, S. L., Heinz, F. X., & Mandl, C. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307145101 · Cited by 116 · see citing works
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
Afkhami, S., Yao, Y., & Xing, Z. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.30 · Cited by 108 · see citing works
Multivalent and Multipathogen Viral Vector Vaccines
Lauer, K. B., Borrow, R., & Blanchard, T. J. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00298-16 · Cited by 107 · see citing works
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
Gsell, P., Camacho, A., Kucharski, A. J., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30541-8 · Cited by 104 · see citing works
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2605 · Cited by 103 · see citing works
Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity
Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.046 · Cited by 101 · see citing works
Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses
Johansson, D. X., Ljungberg, K., Kakoulidou, M., & Liljeström, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029732 · Cited by 98 · see citing works
Frequency of Measles Virus-Specific CD4+and CD8+T Cells in Subjects Seronegative or Highly Seropositive for Measles Vaccine
Ovsyannikova, I. G., Dhiman, N., Jacobson, R. M., et al. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.3.411-416.2003 · Cited by 93 · see citing works
Humoral and Cellular Immune Response to RNA Immunization with Flavivirus Replicons Derived from Tick-Borne Encephalitis Virus
Aberle, J. H., Aberle, S. W., Kofler, R. M., & Mandl, C. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15107-15113.2005 · Cited by 91 · see citing works
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice
Selmi, A., Vascotto, F., Kautz‐Neu, K., Türeci, Ö., Şahin, U., von Stebut, E., Diken, M., & Kreiter, S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1869-7 · Cited by 90 · see citing works
High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial
Liebowitz, D. N., Lindbloom, J. D., Brandl, J. R., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00266-2 · Cited by 89 · see citing works
Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors
Tan, W., Jin, H., West, E., Penaloza-MacMaster, P., Wieland, A., Zilliox, M. J., McElrath, M., Barouch, D., & Ahmed, R. (2012) · Journal of Virology · doi:10.1128/jvi.02055-12 · Cited by 88 · see citing works
CD 8 T‐cell priming upon mRNA vaccination is restricted to bone‐marrow‐derived antigen‐presenting cells and may involve antigen transfer from myocytes
Lazzaro, S., Giovani, C., Mangiavacchi, S., Magini, D., Maione, D., Baudner, B. C., Geall, A. J., Gregorio, E. D., D’Oro, U., & Buonsanti, C. (2015) · Immunology · doi:10.1111/imm.12505 · Cited by 88 · see citing works
Replicon RNA Viral Vectors as Vaccines
Lundstrom, K. H. (2016) · Vaccines · doi:10.3390/vaccines4040039 · Cited by 86 · see citing works
Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge
Jimenez, G. S., Planchon, R., Wei, Q., et al. (2007) · Human Vaccines · doi:10.4161/hv.3.5.4175 · Cited by 85 · see citing works
Attenuated measles virus as a vaccine vector
Zúñiga, A., Wang, Z., Liniger, M., Hangartner, L., Caballero, M., Pavlovic, J., Wild, P., Viret, J. F., Glueck, R., Billeter, M. A., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.064 · Cited by 84 · see citing works
Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine
Halstead, S. B. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1445448 · Cited by 82 · see citing works
Induction of Anti-Tumor Immunity with Epidermal Cells Pulsed with Tumor-Derived RNA or Intradermal Administration of RNA
Granstein, R. D., Ding, W., & Ozawa, H. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00929.x · Cited by 81 · see citing works
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention
Baden, L. R., Karita, E., Mutua, G. N., Bekker, L., Gray, G., Page‐Shipp, L., Walsh, S. R., Nyombayire, J. M., Anzala, O. A., Roux, S., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0880 · Cited by 80 · see citing works
Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
Bialkowski, L., van Weijnen, A., der Jeught, K. V., Renmans, D., Daszkiewicz, L., Heirman, C., Stangé, G. M., Breckpot, K., Aerts, J. L., & Thielemans, K. (2016) · Scientific Reports · doi:10.1038/srep22509 · Cited by 79 · see citing works
Plasmid DNA–Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus
Lalor, P., Webby, R. J., Morrow, J., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/588431 · Cited by 78 · see citing works
The 2015 global production capacity of seasonal and pandemic influenza vaccine
McLean, K. A., Goldin, S., Nannei, C., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.08.019 · Cited by 74 · see citing works
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment
Clarke, D. K., Hendry, R. M., Singh, V., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.06.071 · Cited by 73 · see citing works
General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination
Baldo, A., den Akker, E., Bergmans, H. E. N., et al. (2014) · Current Gene Therapy · doi:10.2174/15665232113136660005 · Cited by 72 · see citing works
Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection
Zohra, F. T., Chowdhury, E. H., Tada, S., Hoshiba, T., & Akaike, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.059 · Cited by 71 · see citing works
Efficacy of Vesicular Stomatitis Virus–Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona
Marzi, A., Hanley, P. W., Haddock, E., Martellaro, C., Kobinger, G., & Feldmann, H. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw218 · Cited by 70 · see citing works
Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans
Peters, W., Brandl, J. R., Lindbloom, J. D., Martínez, C., Scallan, C. D., Trager, G. R., Tingley, D. W., Kabongo, M. L., & Tucker, S. N. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.023 · Cited by 69 · see citing works
Vaccine platform recombinant measles virus
Mühlebach, M. D. (2017) · Virus Genes · doi:10.1007/s11262-017-1486-3 · Cited by 68 · see citing works
An element within the 5′ untranslated region of human Hsp70 mRNA which acts as a general enhancer of mRNA translation
Vivinus, S., Baulande, S., van Zanten, M., Campbell, F., Topley, P., Ellis, J. H., Dessen, P., & Coste, H. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02064.x · Cited by 67 · see citing works
Ebola vaccines in clinical trial: The promising candidates
Wang, Y., Li, J., Hu, Y., et al. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1225637 · Cited by 67 · see citing works
Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2
Steitz, J., Britten, C. M., Wölfel, T., & Tüting, T. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0042-5 · Cited by 65 · see citing works
Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
Green, C., Scarselli, E., Voysey, M., Capone, S., Vitelli, A., Nicosia, A., Cortese, R., Thompson, A., Sande, C., de Lara, C., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008748 · Cited by 60 · see citing works
Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
Walters, A. A., Kinnear, E., Shattock, R. J., McDonald, J. U., Caproni, L. J., Porter, N., & Tregoning, J. S. (2014) · Gene Therapy · doi:10.1038/gt.2014.37 · Cited by 58 · see citing works
Vector-based genetically modified vaccines: Exploiting Jenner’s legacy
Ramezanpour, B., Haan, I., Osterhaus, A. D. M. E., & Claassen, E. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.06.059 · Cited by 58 · see citing works
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
Meyer, J., Harris, S. A., Satti, I., Poulton, I. D., Poyntz, H., Tanner, R., Rowland, R., Griffiths, K., Fletcher, H. A., & McShane, H. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.042 · Cited by 57 · see citing works
Adventitious agents in viral vaccines: Lessons learned from 4 case studies
Petricciani, J. C., Sheets, R., Griffiths, E., & Knežević, I. (2014) · Biologicals · doi:10.1016/j.biologicals.2014.07.003 · Cited by 56 · see citing works
Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses
Estcourt, M. J., Létourneau, S., McMichael, A. J., & Hanke, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200535184 · Cited by 55 · see citing works
Ebola virus disease candidate vaccines under evaluation in clinical trials
Martins, K. A. O., Jahrling, P. B., Bavari, S., & Kuhn, J. H. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1187566 · Cited by 53 · see citing works
Recent advances inEbolavirusvaccine development
Richardson, J. S., Dekker, J. D., Croyle, M. A., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.6.11097 · Cited by 50 · see citing works
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains
CONDIT, R. C., Williamson, A., Sheets, R., Seligman, S. J., Monath, T. P. C., Excler, J., Gurwith, M., Bok, K., Robertson, J. S., Kim, D., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.060 · Cited by 47 · see citing works
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination
Baldo, A., Galanis, E., Tangy, F., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1122146 · Cited by 47 · see citing works
A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge
Grant-Klein, R. J., Deusen, N. M. V., Badger, C. V., et al. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21873 · Cited by 45 · see citing works
Zika Virus Vaccine Development
Morabito, K. M., & Graham, B. S. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix464 · Cited by 45 · see citing works
Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges
Pinschewer, D. D. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14465 · Cited by 44 · see citing works
The Injection of Plasmid DNA in Mouse Muscle Results in Lifelong Persistence of DNA, Gene Expression, and Humoral Response
Armengol, G., Ruíz, L. M., & Ordúz, S. (2004) · Molecular Biotechnology · doi:10.1385/mb:27:2:109 · Cited by 43 · see citing works
Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity
van den Pol, A. N., & Davis, J. N. (2012) · Journal of Virology · doi:10.1128/jvi.01106-12 · Cited by 41 · see citing works
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™
Venkatraman, N., Anagnostou, N. A., Bliss, C. M., Bowyer, G., Wright, D., Lövgren‐Bengtsson, K., Roberts, R., Poulton, I. D., Lawrie, A. M., Ewer, K., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.028 · Cited by 37 · see citing works
Emerging Vaccine Technologies
Loomis, R. J., & Johnson, P. (2015) · Vaccines · doi:10.3390/vaccines3020429 · Cited by 36 · see citing works
Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins
Wang, M., Jokinen, J. D., Tretyakova, I., Pushko, P., & Lukashevich, I. S. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.12.046 · Cited by 36 · see citing works
Cofactors that may influence vaccine responses
de Bruyn, G. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d1fca · Cited by 33 · see citing works
Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine
Medaglini, D., & Siegrist, C. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.008 · Cited by 28 · see citing works
Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis
Klug, B., Robertson, J. S., CONDIT, R. C., Seligman, S. J., Laderoute, M. P., Sheets, R., Williamson, A., Gurwith, M., Kochhar, S., Chapman, L. E., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.015 · Cited by 27 · see citing works
Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
Crank, M. C., Gordon, I. J., Yamshchikov, G. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123969 · Cited by 25 · see citing works
Seasonal and pandemic influenza: global fatigue versus global preparedness
Gilbert, J. A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30466-6 · Cited by 23 · see citing works
Another emerging arbovirus, another emerging vaccine: Targeting Zika virus
Palácios, R., Poland, G. A., & Kalil, J. E. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.059 · Cited by 17 · see citing works

Flagged first, then by citations

Research works printed but not linked: 6

[4]Peiris JS Yuen KY Osterhaus AD Stohr K. The severe acute respiratory syndrome. N Engl J Med. (2003) 349: 2431– 41. 10.1056/NEJMra032498 14681510 · DOI
[30]Fausther-Bovendo H Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. (2014) 10: 2875– 84. 10.4161/hv.29594 25483662 PMC5443060 · DOI
[61]Ledgerwood JE Dezure AD Stanley DA Coates EE Novik L Enama ME. Chimpanzee Adenovirus vector Ebola vaccine. N Engl J Med. (2017) 376: 928– 38. 10.1056/NEJMoa1410863 25426834 · DOI
[69]Marzi A Robertson SJ Haddock E Feldmann F Hanley PW Scott DP. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science (2015) 349: 739– 42. 10.1126/science.aab3920 26249231 PMC11040598 · DOI
[73]Regules JA Beigel JH Paolino KM Voell J Castellano AR Hu Z. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. (2017) 376: 330– 41. 10.1056/NEJMoa1414216 25830322 PMC5408576 · DOI
[116]Venkatesan S Gershowitz A Moss B. Modification of the 5′ end of mRNA. Association of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from vaccinia virus. J Biol Chem. (1980) 255, 903– 908. 6243301

Sorted by citations

A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015 · see citing works
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055 · see citing works
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545 · see citing works
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507 · see citing works
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275 · see citing works
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165 · see citing works
Self-citation
Rapid development and deployment of high‐volume vaccines for pandemic response
Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R., & Shah, N. (2020) · Journal of Advanced Manufacturing and Processing · doi:10.1002/amp2.10060 · Cited by 105 · see citing works
Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies
Armbruster, N., Jasny, E., & Petsch, B. (2019) · Vaccines · doi:10.3390/vaccines7040132 · Cited by 95 · see citing works
Self-citation
From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23 · see citing works
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines · doi:10.3390/vaccines10081251 · Cited by 22 · see citing works
Self-citation
Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18 · see citing works
Self-citation
An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose
Nag, K., Chandra Baray, J., Rahman Khan, M., Mahmud, A., Islam, J., Myti, S., Ali, R., Haq Sarker, E., Kumar, S., Hossain Chowdhury, M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.035 · Cited by 13 · see citing works

Authors: Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B.
Affiliations: CureVac (Germany) (DE)
Corresponding author: Rauch, Susanne
ORCID: Rauch, Susanne
Petsch, Benjamin
Venue: Frontiers in Immunology
Publisher: Frontiers Media SA
Published: 2018-09-19
Volume: 9
Pages: 1963-1963
ISSN: 1664-3224 (ISSN-L)
DOI: 10.3389/fimmu.2018.01963
PMC: PMC6156540
OpenAlex: W2891486793
Cited by: 579
References: 175
Citations by year: 2026: 17 · 2025: 32 · 2024: 55 · 2023: 72 · 2022: 114 · 2021: 159 · 2020: 108 · 2019: 21 · 2017: 1
FWCI: 10.56
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Frontiers in Immunology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: viral vector vaccines, DNA vaccine, mRNA vaccines, pandemic preparedness, outbreak response, vaccine production, emerging pathogens, HIV, SARS, Ebola, Zika virus, antibiotic resistance, global health
MeSH terms: Animals, Communicable Disease Control, Communicable Diseases, Disease Outbreaks, Humans, Vaccination, Vaccines, Global Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New Vaccine Technologies to Combat Outbreak Situations

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Record

About these checks